https://doi.org/10.4081/reumatismo.2015.840

Chronic pain: the burden of disease and treatment innovations

Vol. 67 No. 2 (2015)
Submitted: 28 July 2015
Accepted: 24 September 2015
Published: 23 October 2015
musculoskeletal diseases, chronic pain, opioids, tapentadol.
Abstract Views: 3493
PDF: 2348
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

S. Monti
sara.saramonti@gmail.com
Unità Operativa Complessa di Reumatologia, IRCCS Fondazione S. Matteo, Pavia. Università di Pavia, Italy.
R. Caporali
Unità Operativa Complessa di Reumatologia, IRCCS Fondazione S. Matteo, Pavia. Università di Pavia, Italy.
Musculoskeletal conditions are the most frequent cause of chronic pain and affect around 1 in 5 adults in Europe. When chronic pain occurs, it becomes disease itself, with substantial clinical, social and economic impact. Effi cacy and tolerability problems are encountered with all therapeutic strategies available to treat musculoskeletal pain. This often limits effective analgesia and patients’ long term compliance, with the result that chronic pain is persistently underestimated and undertreated. Tapentadol is a novel, centrally acting analgesic that has been recently commercialized for the treatment of chronic pain. This new molecule, by combining two distinct mechanisms of action, μ-opioid receptor agonism (MOR) and noradrenaline reuptake inhibition (NRI), introduces a new pharmacological class called MOR-NRI. Several studies demonstrated promising results in the management of both nociceptive and neuropathic pain and good tolerability profi le, particularly concerning side effects, compared to traditional opioids. This novel analgesic represents a possible therapeutic option also in the rheumatologic fi eld, particularly in the treatment of osteoarthritis and low back pain.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
S. Monti, Unità Operativa Complessa di Reumatologia, IRCCS Fondazione S. Matteo, Pavia. Università di Pavia
MD
R. Caporali, Unità Operativa Complessa di Reumatologia, IRCCS Fondazione S. Matteo, Pavia. Università di Pavia
Prof, MD

How to Cite

Monti, S., & Caporali, R. (2015). Chronic pain: the burden of disease and treatment innovations. Reumatismo, 67(2), 35–44. https://doi.org/10.4081/reumatismo.2015.840

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.